Continuous Weekly Adalimumab is the Optimal Long-Term Strategy for Patients with Moderate-to-Severe Hidradenitis Suppurativa: Results from the PIONEER Open Label Extension Trial

Main Article Content

Alexa B Kimball
Martin M Okun
Gerit Mulder

Keywords

adalimumab, hidradenitis suppurativa, therapeutics

Abstract

Abstract Not Available

 

Disclosures: Study supported by AbbVie.